Good news! Cancer is history (soon)!
"The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey. ...
The jab uses messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime the body to fight cancer cells expressing these markers. ...
Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease. ..."
Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease. ..."
"BNT116 is a mRNA cancer vaccine candidate encoding six shared antigens frequently expressed in non-small cell lung cancer (“NSCLC”), aiming to trigger a strong and precise immune response in patients with this tumor type. BNT116 is currently being evaluated in a Phase 1 trial in several cohorts for dose confirmation as monotherapy as well as in combinations in patients with advanced or metastatic NSCLC. The candidate is also being investigated in a Phase 2 trial in combination with cemiplimab, a PD-1 inhibitor, and cemiplimab alone as first-line treatment for patients with metastatic NSCLC. Interim Phase 1 study data show encouraging initial clinical activity in heavily pre-treated patients and a tolerable safety profile."
No comments:
Post a Comment